Pedro A. Velasquez-Mieyer, M.D. – FDA Inspection, Sep 13, 2024

Record Details

This FDA Inspection record concerns Pedro A. Velasquez-Mieyer, M.D., with an inspection on September 13, 2024, issued by the New Orleans District Office, covering human drugs.

Company: Pedro A. Velasquez-Mieyer, M.D.
Inspection Date: September 13, 2024
Product Type: Human Drugs
Office: New Orleans District Office
People: Abigail M. Cruz (Issuing Officer)
Joann M (FDA Associated Person)
Kellie B. Kelm
Kellie R. Riggs (Company Rep)

View Company Profile

ID · d1fe06c6-a4a9-495f-ac49-654b30e7c7af

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number: 1249188
FDA center: Human Drugs
Project area: Bioresearch Monitoring: Human Drugs
Outcome: Form 483 issued, view the record

FDA Citations

21 CFR 312.60FD-1572, protocol compliance

Full citation text and observation details available on the Dashboard.

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Pedro A. Velasquez-Mieyer, M.D.

FDA Inspection

Pedro A. Velasquez-Mieyer, M.D.September 13, 2024